AI Article Synopsis
Article Abstract
In the HOVON68 trial comparing subcutaneous low-dose alemtuzumab (LD-A) used together with fludarabine (F) and cyclophosphamide (C) with FC alone in high-risk chronic lymphocytic leukemia (CLL), LD-AFC resulted in significantly more clinical and molecular responses than FC, but also in more opportunistic infections. In a subgroup analysis of alemtuzumab trough levels during treatment by a sensitive enzyme-linked immunosorbent assay (ELISA) method, detectable levels were found in 4/6 complete and 0/3 partial responders. A relationship between alemtuzumab plasma levels, response and duration of lymphocytopenia was evident. We hypothesize that following combination therapy, the response may not be a function of the alemtuzumab levels, but the opposite, that plasma alemtuzumab levels are a function of the efficacy of the entire treatment, and the fewer leukemic target cells that are remaining, the higher are the levels of plasma alemtuzumab. This concept may well provide a guide for alemtuzumab dosage in future trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2012.720373 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.
Leuk Lymphoma
November 2024
Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
For fixed-duration therapies against chronic lymphocytic leukemia (CLL), undetectable measurable residual disease (MRD) predicts overall and progression-free survival more accurately than complete remission. For indefinite therapies, MRD status can direct discontinuation of treatment. We systematically reviewed the relationship between antineoplastic drug exposures and undetectable MRD in CLL.
View Article and Find Full Text PDFImpact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence.
PLoS Pathog
August 2024
Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Persistence of the rebound-competent viral reservoir (RCVR) within the CD4+ T cell compartment of people living with HIV remains a major barrier to HIV cure. Here, we determined the effects of the pan-lymphocyte-depleting monoclonal antibody (mAb) alemtuzumab on the RCVR in SIVmac239-infected rhesus macaques (RM) receiving antiretroviral therapy (ART). Alemtuzumab administered during chronic ART or at the time of ART initiation induced >95% depletion of circulating CD4+ T cells in peripheral blood and substantial CD4+ T cell depletion in lymph nodes.
View Article and Find Full Text PDFPatterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis.
Mult Scler Relat Disord
August 2024
Biogen, Cambridge, MA, USA.
Article Synopsis
- Pregnancy is a key consideration for individuals with multiple sclerosis (pwMS) since MS typically begins during the child-bearing age, affecting Disease-Modifying Therapy (DMT) choice before, during, and after pregnancy.
- This study analyzed data from the US MarketScan Claims Database, focusing on women aged 18-55 with MS from January 2016 to April 2021, aiming to understand DMT use and relapse patterns throughout the pregnancy and postpartum periods.
- Results showed that DMT usage decreased significantly during pregnancy, particularly among Medicaid patients, who had lower DMT utilization compared to commercially insured patients, indicating a need for better guidance on MS management during these times.
Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?
Clin Exp Immunol
June 2024
Centre for Rheumatology, UCLH, London,UK.
Article Synopsis
- - B and T cells work together to promote autoimmune diseases (AID), leading to challenges in effective treatment with existing B-cell depletion therapies like rituximab and ocrelizumab.
- - Some patients with AID still have high levels of certain B cells that anti-CD20 treatments fail to target, resulting in persistent disease; this is complicated by the fact that B-T cell collaboration occurs primarily in areas where treatment access is limited.
- - Novel therapies utilizing T cells, such as CAR T-cell therapy and T-cell engagers, show promise in managing refractory AID by disrupting the interaction between B and T cells and might offer better outcomes for patients resistant to standard treatment.
Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease.
Br J Haematol
April 2024
Department of Neurology, Hopital Bicêtre, APHP, Université Paris Saclay, Le Kremlin-Bicêtre, France.
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening disease that may result from drug exposure. We report a case of iTTP occurring in a 39-year-old patient, 45 months following introduction of the anti-CD52 lymphoid cell depleting monoclonal antibody alemtuzumab, to treat a relapsing-remitting multiple sclerosis. Treatment consisted in plasma exchange, corticosteroids and caplacizumab, allowing clinical remission 3 months after the diagnosis, attested by the absence of thrombocytopenia and recovery of ADAMTS-13 activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!